GKOS vs. HAE, MMSI, GMED, AXNX, INSP, IRTC, PRCT, TNDM, PEN, and NARI
Should you be buying Glaukos stock or one of its competitors? The main competitors of Glaukos include Haemonetics (HAE), Merit Medical Systems (MMSI), Globus Medical (GMED), Axonics (AXNX), Inspire Medical Systems (INSP), iRhythm Technologies (IRTC), PROCEPT BioRobotics (PRCT), Tandem Diabetes Care (TNDM), Penumbra (PEN), and Inari Medical (NARI). These companies are all part of the "surgical & medical instruments" industry.
Glaukos (NYSE:GKOS) and Haemonetics (NYSE:HAE) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk, media sentiment and community ranking.
Glaukos has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500.
In the previous week, Haemonetics had 26 more articles in the media than Glaukos. MarketBeat recorded 37 mentions for Haemonetics and 11 mentions for Glaukos. Glaukos' average media sentiment score of 0.63 beat Haemonetics' score of 0.56 indicating that Glaukos is being referred to more favorably in the media.
Glaukos currently has a consensus target price of $108.64, suggesting a potential upside of 1.09%. Haemonetics has a consensus target price of $108.67, suggesting a potential upside of 12.85%. Given Haemonetics' higher possible upside, analysts plainly believe Haemonetics is more favorable than Glaukos.
Glaukos received 41 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 64.54% of users gave Glaukos an outperform vote while only 60.89% of users gave Haemonetics an outperform vote.
Haemonetics has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.
Haemonetics has a net margin of 8.98% compared to Glaukos' net margin of -43.15%. Haemonetics' return on equity of 22.25% beat Glaukos' return on equity.
99.0% of Glaukos shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 6.4% of Glaukos shares are held by company insiders. Comparatively, 1.8% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Haemonetics beats Glaukos on 10 of the 18 factors compared between the two stocks.
Get Glaukos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
